1. Home
  2. IDT vs NTLA Comparison

IDT vs NTLA Comparison

Compare IDT & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IDT Corporation Class B

IDT

IDT Corporation Class B

HOLD

Current Price

$51.79

Market Cap

1.2B

ML Signal

HOLD

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$9.73

Market Cap

986.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IDT
NTLA
Founded
1990
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
986.9M
IPO Year
1996
2016

Fundamental Metrics

Financial Performance
Metric
IDT
NTLA
Price
$51.79
$9.73
Analyst Decision
Buy
Analyst Count
0
22
Target Price
N/A
$19.83
AVG Volume (30 Days)
248.4K
4.0M
Earning Date
12-04-2025
11-06-2025
Dividend Yield
0.47%
N/A
EPS Growth
10.35
N/A
EPS
3.22
N/A
Revenue
$1,244,681,000.00
$57,528,000.00
Revenue This Year
$0.77
$1.96
Revenue Next Year
N/A
N/A
P/E Ratio
$15.98
N/A
Revenue Growth
2.52
33.52
52 Week Low
$44.77
$5.90
52 Week High
$71.12
$28.25

Technical Indicators

Market Signals
Indicator
IDT
NTLA
Relative Strength Index (RSI) 54.28 47.58
Support Level $50.60 $8.74
Resistance Level $54.08 $9.55
Average True Range (ATR) 2.08 0.58
MACD 0.27 0.31
Stochastic Oscillator 66.08 84.07

Price Performance

Historical Comparison
IDT
NTLA

About IDT IDT Corporation Class B

IDT Corp is a multinational holding company. It operates in the telecommunications and payment industries. It has four reportable business segments, Fintech, National Retail Solutions; net2phone and Traditional Communications, The Fintech segment is comprised of National Retail Solutions (NRS), an operator of a nationwide point of sale (POS) network providing payment processing, digital advertising, transaction data, and ancillary services, and BOSS Money, a provider of international money remittance and related value/payment transfer services. The net2phone segment provides unified cloud communications and telephony services to business customers.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: